ࡱ> IKH 1bjbj 7*  8:VPrL,>w wwwRwwww Kvw 0Pwwwww<wP :    FOR IMMEDIATE RELEASE Contact: Jeanette Krebs July 15, 2015 Phone: (717) 214-2200 Email:  HYPERLINK "mailto:krebs@thebravogroup.com" \h krebs@thebravogroup.com HYPERLINK "mailto:krebs@thebravogroup.com" \h  NEW CONFERENCE WILL PROMOTE ENGINEERING AND BUSINESS OPPORTUNITIES IN INDUSTRIAL BIOTECHNOLOGY Society for Biological Engineers workshop explores commercial and technical aspects of industrial biotechnology, September 2829, in San Diego NEW YORK CITY-The Society for Biological Engineers (SBE), a subsidiary of the 91˶Ƶ (AIChE), is organizing a new workshop titled Technology Challenges and Opportunities in Commercializing Industrial Biotechnology, where engineers, scientists, and other stakeholders in business and industry will discuss the latest wave of opportunities that have emerged from the biotechnology revolution. The workshop will convene at the Bahia Hotel in San Diego, California, on Sept. 2829 and will highlight commercial opportunities and technical challenges in the developing field of industrial biotechnology. At the two-day event, technology experts and business leaders in the chemicals, biotechnology, and energy arenas will gather with researchers and representatives from government and investment companies to discuss the techniques, economics, engineering design, and international perspectives involved in industrial biotechnology. The event will integrate technical information with economic analyses, providing insight into industrial biotechnology as a means of manufacturing and effectively marketing fuels, chemicals, and a range of new products. Jeff Lievense, executive vice president for Process Technology at Genomatica, a San Diego-based biotech company, and Brian Davison, chief scientist for Systems Biology and Biotechnology at Oak Ridge National Laboratory, will co-chair the event. This workshop offers a deep dive into the science and engineering of commercializing industrial biotechnology, says workshop co-chair Lievense. Attendees will learn about technology best practices, feedstock choices, and real economics, and hear first-hand case studies that show how bioprocesses work, predictably and at scale all presented by people who have done the work successfully. Setting the stage for the discussions to follow, the workshops opening keynote speeches on Sept. 28 will be given by Doug Cameron, co-president and director of First Green Partners, a Minneapolis, Minnesota-based company that leverages advances in science and technology applied to agriculture, and Geoff Duyk, partner and managing director of TPG Biotech, a developer of alternative and renewable technologies. Industrial biotechnology involves working with living cells to optimize biochemical pathways for use in manufacturing a variety of products, and is one of the most promising approaches to pollution prevention, resource conservation and energy production. The emergence of industrial biotechnology as a growth area stems from a series of related developments in cell-based biology, including genomics, proteomics, bioinformatics, and metabolic engineering. The glob al industrial biotechnology market is already large, amounting to about $150 billion in annual sales. Developed to its full potential, industrial biotechnology and its products may have enormous impacts on world health and energy production, offering businesses ways to improve efficiency and reduce costs while protecting the environment. In addition, the new products generated by applications of biotechnology on the industrial scale may open doors to unprecedented commercial opportunities. The launch of the Technology Challenges and Opportunities in Commercializing Industrial Biotechnology workshop is timely, Lievense notes, because the modern practice of industrial biotechnology is relatively new, and its benefits are still not yet fully understood by industry, policymakers, investors and consumers. The workshop will increase collaborations among those very thought-leaders and participants, including investors which is a necessary step for the continued growth and success of industrial biotechnology. Complete program and registration information is available at  HYPERLINK "http://www.aiche.org/cib" \h www.aiche.org/cib # # # About SBE: Established in 2004, the Society for Biological Engineering is a technological community for engineers and applied scientists integrating biology with engineering. Members of SBE come from a broad spectrum of industries and disciplines and share in SBEs mission of realizing the benefits of bioprocessing, biomedical and biomolecular applications.  HYPERLINK "http://bio.aiche.org" \h http://bio.aiche.org. About AIChE: AIChE is a professional society of more than 50,000 chemical engineers in 100 countries. Its members work in corporations, universities and government using their knowledge of chemical processes to develop safe and useful products for the benefit of society. Through its varied programs, AIChE continues to be a focal point for information exchange on the frontiers of chemical engineering research in such areas as energy, sustainability, biological and environmental engineering, nanotechnology and chemical plant safety and security. More information about AIChE is available at www.aiche.org.     PAGE1 @AFHjkz{> I V X g ʺʲ~m\mKm!h-6CJOJPJQJ^JaJ!h 5CJOJPJQJ^JaJ!h-5CJOJPJQJ^JaJ3jh->*B*CJOJPJQJU^JaJph*h->*B*CJOJPJQJ^JaJphh-jh-Uh=CJOJPJQJ^JaJh-CJOJPJQJ^JaJ!h->*CJOJPJQJ^JaJh_p jh/h>UmHnHuAkW X h j |}uv1$$a$0]0$a$g h i j &)OQ_z{}tv y$h-56CJOJPJQJ^JaJ3jh->*B*CJOJPJQJU^JaJphU*h->*B*CJOJPJQJ^JaJphUh-jh-U'h-B*CJOJPJQJ^JaJphh CJOJPJQJ^JaJh-CJOJPJQJ^JaJh_p* !#$-./  ! $ !a$d$a$1$qr!"$%)*+,./01ǫ}y}y}y}ypyh=mHnHuh&ljh&lU$h-56CJOJPJQJ^JaJ$h-6>*CJOJPJQJ^JaJ6jh-6>*B*CJOJPJQJU^JaJph-h-6>*B*CJOJPJQJ^JaJphh-jh-Uh_p!h-6CJOJPJQJ^JaJ /01d50P/ =!"#$% Dp,"DdTh  A? nOAF3zJN8p2rRj2PEUn8jgRwcwKVODSoWt_jynPFhZZotnJy_B9PQ9BnVBz9lejw0zl-lXATluF0IYtX42mw0wK9l68-E7EUA-v_ElUb4J399U_wsUGc21NNbbng60nHlQz3KOSwimage01.pngDescription: https://lh4.googleusercontent.com/OAF3zJN8p2rRj2PEUn8jgRwcwKVODSoWt_jynPFhZZotnJy_B9PQ9BnVBz9lejw0zl-lXATluF0IYtX42mw0wK9l68-E7EUA-v_ElUb4J399U_wsUGc21NNbbng60nHlQz3KOSw"b@>X,LDDn@>X,LDPNG  IHDRRs/jIDATx] pyV3$i'>d7Li;MdbKmN8vq$OƶNm*8tRdʖL&uDҲ$KCHIA).-E Aw|/N8q.ĉN8qĉN8qH䞛$v`w6NXs Rt+eݰN ~p3ni.tNG6f)2Ƽwۡ,@edFR.ޱzX鮆T~5VmniҦ:8dCrבy=tc]n"Z?Pm턷mυe|6!Fв B+f"!`1Yb2OLk'wP:wo rηѝۮ¯ M A$)ACbDĕʮإO?ӆXc81c " p灪N4X:"q1?8^@@`칏kWyA$IA9`qLθ2:I$c &f1B"="h {B-ɩ'5;`cY75E[_ DD4 E4v.Yw#wjx?j> ;YׇLdrGj;Ƥ4Lh^]t ø8`nSh8`vưyA8>f;$B~"sefj{0@8RLbXAeJW "۪{CWE>dbܓ]y>Z 37 'bϏV mvYwH&>1"Ǧ۳-0 AS\@ƠF#h_E#2A@kw#:}&ljmG1SSZgD2N(j 2 Q˸HnWrN½xM!r*'ə]@ۂ;P}",?w2[!Q@YW?x"z+RCv((0郋!龓DT.krMQ(UÓf5{96qf皩X څV 9 (qp*NK D*@bE5CNoa?8ğ2u#Ts"n8|>Ef^:9ƅάP/>Ri D,6~O Ra[vWLf"b "_}: R_B?'S "-Sb)Z[a8$?48lkx\0 '{(s@Gqzss~mh*_I}E -󕶡9uܳ\lAc& z0$NA$SRdo6I E^V.8!؁N萭%`n%h\8#@ !*=qy:@ 8*r 캰'*֝ w@9MSnqRG8TZ#g:Fr2ٱ[AyPT9T Gjr "{bZ* B=M7$KmrfJA,zq0LFyIͰp" P=@Oڊ1D_hU PgVZg#pZ5)`c^>ccz^&Y{ƻQyq.l^DPeyáADx'@Mnx)^h 2;eK9:䞣0BO4vGaL P$'NOʩy 2d Cֳ A䴊CH1 /ޭT)ð8^BI!&.o$ 5e=7 E ",N9\ s2|aHA1ZI*S&¸*x3TTҪ ڝHCq!T|ɨ! êC $ 4k 2 P ?T9ccrY QK̄;5L)]8/$'I( O9u$5CB8x @Y\iު2465f+)>FuzcĽs2AN6 u u߬"1M:tG@΄/eZp >7!<;a;ΫJS ykcҏ hP\+("t?Tè"c*< .i"j!6b% "݂6Mh"${XC,: TXFMU]qru3286:g_,Tt)Acn#(XqP1{d!,AYSDJ5XZ$DPK<`JH߃6YH:TDd'zj "5 0O $̴,:leơe/r4RK2[b"x".ڙ%TAOmeVD9yx5$`_@8'0y;0#k "xHs$2h!XXMLA$~@ YnS;7 7&BU䈉Wy渂2dE ^ rSD)Zvm!D44"N.owDU#Zs$?gk.ٟ$2{~|s9aXrcwOA*\]>n XNgIxHivI?Q (z .5{l !5Z P@jyr,0.&B$̼ZؤPΩkB,X}p յ\q3D%A+AS'}A<\18Y tUfZEb ):hTʓzH?)`Ypp 򚆂fT"v!i@-q.)ND:T@'!wbQXi0l\@Ws 4 É9 h՞@MX5'k\a-DbK詊 )ZdT1K&`LyzL>21twudV|М9X쫠 B2.e *t]۽s*;Iu9ڄǸYa6:"I1!tB.@^Pg+ͨ%2C}I.8J;F`;(ZAT;)p*5Pbk "4`qD߾Q̕PZ Z&_QuHiZH Y,r'"!71#K@0x {N:|KM!:"/[cT5]^l F=jѠ?褁LJ@$_h,9~; 68r4@DF<_c(D*asI] sS3t-ɑ8JLV<1ʙSG6+:^<#ߡ}bj"zh`ܷrOvjee0·gDt`bA'sOz'hJAK40;#<~)aboVqDn0odCuВG8j eZaY10DD6ÍdpLJ JAD5yKU&  4rw[y&-蕲,BkIJ)06"u Pc[vRoS趢c:6q6:N8,pK├8pĉN8qĉN8qĉpA^Ved@8 i:h=koCka尜)გf)>׳f!۪Z!#=9+gLJ:ұޚ,!~`0+®ݹ`۳ղƲ͍HǽܢKMٜ׸շ}%f<ַ7wE:D\p(Iiv+PL|~.MY-2vIu}^*ڢDɶ箛"J%<Yy<2к|r}D6%Iic.],ɴCT"N D|w}D<?u48NHW3k l` ,@zssUMے prxTzՐV0n2ݱddegCVV)of:9cUlԺTh]~F;/O)ɸxO6t e ڜyߒm ץI\埭@A0H[}?0f*E2ݏ%pH#OW@IIT]'j}-ō]Qbǜ$/o$51DʨXܷ}YXp*<Ht@cɰ"ʧH!|rsKrlby~CR|H?Xv ǴX Cd Tߩm+.Bu>Ok8`~88 7qu68s@!oA6"'k>Mr*q7@Vd9K`C8)h&L^qi yS)ȸOXNZ+<Q}Nn5ӿd2xV;|θ>"WάL pٗ"a ^"xm˵i.5 u:2Xp}>~xwv'O*'8;~brkE:}4QDv. y2=i QVHiRhTr~֥f?:(v xC{Z]H;濏l "eKK'mb?E) حV:]wD(C02@C`# 26Ú$0QlڃȆ>eij߄Դ=P'ߴ$+wSߑwʉ"*dՒ [;Kom"]>:Ψ(F<)ӐF@hp@v6"ɪ;V "s׉~(}l,%=2K!.(@ęh{ "grq(Q0q&P}PYLJf^ ߍ9 zP@_fU-ݝ{سA w+${2mdfn8Xp3"{wK;*ݳRͳhmߚ9$ H;b$ B;[e[CY4r<ʼnmP"݁Gd:imWDyKҝݳb Ö_k" DHǞ3Zrߗ,e5w,h%`x w^Pt=Tau "@~]*L^R6jАI鄴lË_g1áF9,D+t4',]K^v᳷Zt (=QnZ B'tbg[3DYiq`f~s^32p ' /.V|A.;w7Lby$-G ?|3}"=4@#n :öM737K>梨>|v]t4Te?xynAD ]'XQmvl3)vV;V9Xbim J.RhGiknVYԫJ6iXa_=MVO;X|@?K-kd~G%xC-[nf8q*YJ'J_NWv|OxIENDB`666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~$OJPJQJ^J_HmH nH sH tH N`N Normal!B*CJ_HaJmH phsH tH L@L Heading 1$$xm$ 5CJ0aJ0L@L Heading 2$$hPm$ 5CJ$aJ$L@L Heading 3$$Pm$ 5CJaJL@L Heading 4$$(m$ 5CJaJL@L Heading 5$$(m$ 5CJaJL@L Heading 6$$(m$ 5CJaJDA D Default Paragraph FontRiR 0 Table Normal4 l4a (k ( 0No List NoN normal!B*CJ_HaJmH phsH tH D>@D Title$$xm$ 5CJHaJHbJ@b Subtitle$$hPm$$6B*CJ0OJPJQJ^JaJ0phfffL@"L >0 Balloon TextCJOJQJ^JaJNo1N >0Balloon Text CharCJOJQJ^JaJPK!pO[Content_Types].xmlj0Eжr(΢]yl#!MB;.n̨̽\A1&ҫ QWKvUbOX#&1`RT9<l#$>r `С-;c=1g'}ʅ$I1Ê9cY<;*v7'aE\h>=,*8;*4?±ԉoAߤ>82*<")QHxK |]Zz)ӁMSm@\&>!7;ɱʋ3װ1OC5VD Xa?p S4[NS28;Y[꫙,T1|n;+/ʕj\\,E:! t4.T̡ e1 }; [z^pl@ok0e g@GGHPXNT,مde|*YdT\Y䀰+(T7$ow2缂#G֛ʥ?q NK-/M,WgxFV/FQⷶO&ecx\QLW@H!+{[|{!KAi `cm2iU|Y+ ި [[vxrNE3pmR =Y04,!&0+WC܃@oOS2'Sٮ05$ɤ]pm3Ft GɄ-!y"ӉV . `עv,O.%вKasSƭvMz`3{9+e@eՔLy7W_XtlPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-!pO[Content_Types].xmlPK-!֧6 -_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!!Z!theme/theme/theme1.xmlPK-! ѐ'( theme/theme/_rels/themeManager.xml.relsPK]# 1* g 1/1zq1XXXX !8@0( qo3s  B S  ?FH !#$/2Aj. !#$/2::: =HpQ&l_pX r- >@HHLW}((HH1@UnknownGTimes New Roman5Symbol3 Arial7Cambria7GeorgiaC  PLucida GrandeACambria Math 1hWz7g]z7g% &% &0B#HP $P'_p!xx AIChEAIChE Oh+'0\   $ 0<DLT'AIChE Normal.dotmAIChE6Microsoft Macintosh Word@F#@R^@^5% ՜.+,D՜.+,T hp  ',91˶Ƶ&   Title 8@ _PID_HLINKS'AI http://bio.aiche.orgKEhttp://www.aiche.org/cibX|mailto:krebs@thebravogroup.comX|mailto:krebs@thebravogroup.com  !"#$%&')*+,-./012345679:;<=>?ABCDEFGJRoot Entry F KLData ,"1Table(WordDocument7*SummaryInformation(8DocumentSummaryInformation8@CompObj` F Microsoft Word 97-2004 DocumentNB6WWord.Document.8